Efficacy of up to 4 years of tralokinumab in adults with moderate‐to‐severe atopic dermatitis
These data suggest that tralokinumab plus optional TCS/TCI provides long-term stable disease control, equivalent to no-to-mild disease, in a subgroup of adults with moderate-to-severe AD who completed 1 year of treatment in parent trials and up to 3 years in ECZTEND.
Authors
- Kristian Reich (ORCID: https://orcid.org/0000-0001-5248-4332)
- Melinda Gooderham (ORCID: https://orcid.org/0000-0001-8926-0113)
- Christian Bjerregård Øland (ORCID: https://orcid.org/0000-0001-8929-1761)
- Eric L. Simpson (ORCID: https://orcid.org/0000-0003-0853-0252)
- Thomas Werfel (ORCID: https://orcid.org/0000-0002-7957-4917)
- Norito Katoh (ORCID: https://orcid.org/0000-0002-3498-2482)
- Le Gjerum (ORCID: https://orcid.org/0000-0002-5849-1397)
- Chih-ho Hong (ORCID: https://orcid.org/0000-0001-9963-8319)
- Richard G. Langley (ORCID: https://orcid.org/0000-0003-4730-2164)
- J.F. Silvestre (ORCID: https://orcid.org/0000-0002-8532-6338)
- Andrew Blauvelt (ORCID: https://orcid.org/0000-0002-2633-985X)
- Ann‐Marie Tindberg
- Ketty Peris (ORCID: https://orcid.org/0000-0003-1957-6600)
- Mahreen Ameen (ORCID: https://orcid.org/0000-0002-7603-3007)
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Dalhousie University (CA)
- University of British Columbia (CA)
- Universität Hamburg (DE)
- Oregon Health & Science University (US)
- Royal Free London NHS Foundation Trust (GB)
- Queen's University (CA)
- Surrey Memorial Hospital (CA)
- Medizinische Hochschule Hannover (DE)
- Kyoto Prefectural University of Medicine (JP)
- SKiN Health (CA)
- Maryland Department of Natural Resources (US)
- University Medical Center Hamburg-Eppendorf (DE)
- North Medical Center (JP)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- Leo Pharma (Denmark) (DK)
- Catholic University of America (US)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1111/jdv.70165
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00